Furthermore, PHF6 was found to be a prognostic disadvantage factor for DSS in LIHC, pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), and PAAD (Figure 2B). Here, PHF6 is linked to paraganglioma.